Daring Denali Therapeutics MPS II Study Delivers!
Denali Therapeutics announced primary analysis results from a Phase 1/2 study of tividenofusp alfa (DNL310) in 47 participants with...
CytoDyn Shows Statistically Significant Fibrosis Reversal
CytoDyn Inc. announced positive preclinical results for leronlimab, demonstrating a statistically significant reversal of liver fibrosis in three separate...
Wave Life Sciences Initiates Phase 1 Inlight Trial of WVE-007 in Obesity
Wave Life Sciences has initiated a Phase 1 clinical trial, INLIGHT, for WVE-007, a novel RNA interference (RNAi) therapy...
Tonix CD40L MAb Shows Promise in Kidney Transplant Rejection
Tonix Pharmaceuticals announced positive topline results from its Phase 1 single ascending dose trial of TNX-1500, an anti-CD40L monoclonal...
Trinity Biotech CGM Trial Shows Landmark First-Day Accuracy Gains
Trinity Biotech announced positive findings from a pre-pivotal trial of its next-generation continuous glucose monitoring (CGM) system, demonstrating significant...
Northwestern Medicine First in Aclarion’s Clarity Trial
Aclarion, Inc. launched its pivotal CLARITY trial at Northwestern Medicine, a leading clinical trial research center. The CLARITY trial...
FDA Approves Lipella’s LP-310 for Oral Lichen Planus
Lipella Pharmaceuticals (Nasdaq: LIPO) has received FDA approval for an Expanded Access Program (EAP) for LP-310, an oral rinse...
Vaxxas Appoints Global Vaccine Experts for Needle-Free Trials
Vaxxas, a clinical-stage biotech company, has appointed three prominent vaccine experts as advisors to guide product development and strategy....
AgelessRx Launches Oral GLP-1 Drops for Metabolic Health
AgelessRx has launched oral sublingual drops for the GLP-1 receptor agonists Semaglutide and Tirzepatide, offering a non-injectable alternative for...
Enveda’s First-in-Class ENV-294 for Asthma: A Breakthrough
Enveda Biosciences is testing its lead drug candidate, ENV-294, for asthma, marking its second clinical application after atopic dermatitis....